# Patient-Trial Match Report

*Generated: 2026-01-05 18:32:32*

## Patient Profile

- **Age**: 55
- **Sex**: Male
- **Cancer Type**: gastric cancer
- **Biomarkers**: HER2 positive, MSI-High

**Clinical Description**:
> 55-year-old male with metastatic gastric adenocarcinoma, HER2-positive (IHC 3+) and MSI-High/dMMR. First-line FOLFOX + trastuzumab + pembrolizumab achieved complete response lasting 16 months. Now recurred with peritoneal carcinomatosis and malignant ascites requiring paracentesis q2 weeks. Declining appetite and early satiety. Lost 8kg over past 2 months. Seeking next-line options that leverage both HER2 targeting and immunotherapy. Mild hypoalbuminemia (3.1). Family history notable for Lynch syndrome (MLH1 mutation in family, patient confirmed carrier).

- **Location Preference**: United States

## Search Summary

- **Search terms used**: 11
- **Total trials evaluated**: 100
- **Excluded by fast filter**: 42
- **LLM scored**: 58

## ðŸŸ¢ HIGH Likelihood (8 trials)

### [NCT01514045](https://clinicaltrials.gov/study/NCT01514045)

**The Gastric Cancer Foundation: A Gastric Cancer Registry**

- **Sponsor**: Stanford University
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has histologically proven gastric cancer.
- Patient is 55 years old, which is above the minimum age of 18.
- Patient has a confirmed germline mutation (MLH1) relevant to family history considerations.

**Assessment:**
> The patient's cancer type matches the trial focus on gastric cancer. Since the trial is a registry collecting data that includes patients with a history of gastric cancer or family history, the patient qualifies based on his diagnosis and family history as a confirmed carrier of an MLH1 mutation.

---

### [NCT04762953](https://clinicaltrials.gov/study/NCT04762953)

**Phase II Trial of Sequential Systemic Therapy Plus Intraperitoneal Paclitaxel in Gastric/GEJ Cancer Peritoneal Carcinomatosis (STOPGAP)**

- **Sponsor**: University of California, Irvine
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Cancer type: gastric cancer matches the trial conditions studied.
- Patient has peritoneal carcinomatosis.
- Age: 55 is within the acceptable age range (18-75).
- ECOG performance status: 2 is acceptable.
- Duration of prior systemic treatment: patient received first-line therapy (FOLFOX + trastuzumab + pembrolizumab) for 16 months without visceral metastatic progression.

**? Uncertainties:**
- Adequate organ and marrow function criteria need confirmation (e.g., leukocytes, neutrophil count, platelets, bilirubin, AST/ALT, creatinine, hemoglobin, and albumin levels).

**Assessment:**
> The patient's cancer type aligns with the trial's focus, and they have experienced prior treatment, which fits the inclusion criteria. However, organ function results are not provided, leaving room for uncertainty.

---

### [NCT04314401](https://clinicaltrials.gov/study/NCT04314401)

**Cancer Moonshot Biobank Research Protocol**

- **Sponsor**: National Cancer Institute (NCI)
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Diagnosis of gastric cancer, stage IV
- ECOG status of 2
- Age is 55

**Assessment:**
> The patient's gastric cancer type matches the trial focus on gastric carcinoma, specifically stage IV. The patient is not treatment-naive but his prior therapies align with eligibility for previously treated patients. The ECOG status and age also meet the trial's requirements.

---

### [NCT04221893](https://clinicaltrials.gov/study/NCT04221893)

**Phase II Study of Hypofractionated Radiation Therapy to Augment Immune Response in Patients With Metastatic GastroIntestinal Malignancies Progressing on Immune Therapy (ARM-GI)**

- **Sponsor**: University of California, San Francisco
- **Phase**: Not Applicable
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has metastatic gastric cancer, which is included in the trial conditions.
- Patient is HER2-positive, which aligns with the trial's focus on aggressive treatments.
- Patient is receiving pembrolizumab immunotherapy and has progressive disease.
- ECOG status of 2 is acceptable for the trial.

**? Uncertainties:**
- Adequate organ function is not explicitly stated in the profile.

**Assessment:**
> The patient's cancer type and history match the trial's focus on metastatic gastric cancer, and they are currently treated with immunotherapy with evidence of progressive disease, which meets the required conditions for trial eligibility.

---

### [NCT03740256](https://clinicaltrials.gov/study/NCT03740256)

**A First in Human Phase I Trial of Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR T Cells in Patients With Advanced HER2 Positive Solid Tumors**

- **Sponsor**: Baylor College of Medicine
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Cancer type: gastric cancer matches the trial condition
- Patient is HER2 positive (IHC 3+), meeting the biomarker criteria
- Disease is deemed unsuitable for curative treatments as per profile
- Patient has progressed after standard first line therapy with FOLFOX + trastuzumab + pembrolizumab
- Patient has ECOG status of 2 which is acceptable
- Patient is 55 years old, above the minimum age requirement

**? Uncertainties:**
- Adequate organ function data is not provided in the profile

**Assessment:**
> The patient's gastric cancer diagnosis matches the trial's focus on HER2 positive disease. The patient is not treatment-naive as they have received prior therapies, which aligns with the trial's acceptance of previously treated patients. Other criteria such as HER2 positivity and ECOG status are satisfied, although organ function details need verification.

---

### [NCT06828588](https://clinicaltrials.gov/study/NCT06828588)

**Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy**

- **Sponsor**: Vanderbilt-Ingram Cancer Center
- **Phase**: Early Phase 1
- **Status**: Not yet recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has HER2-positive gastric cancer, matching the trial's condition for HER2 + gastric cancer.
- Patient's cancer is metastatic and unresectable, aligning with trial inclusion criteria.
- Patient confirmed HER2 positivity with IHC (IHC 3+).
- Patient has documented measurable disease (peritoneal carcinomatosis).

**? Uncertainties:**
- Patient's life expectancy based on ECOG 2 status could be uncertain.
- Liver function is not provided, making organ function an uncertainty.

**Assessment:**
> The patient's gastric cancer type and HER2 positivity clearly align with the trial's focus. The patient is recurrent after first-line treatment, which allows participation per trial criteria for previously treated patients. There are some uncertainties regarding overall life expectancy and organ function, but these do not detract significantly from eligibility.

---

### [NCT05274048](https://clinicaltrials.gov/study/NCT05274048)

**A Multi-Center Phase I Trial of Neratinib and Fam-trastuzumab Deruxtecan in Advanced Refractory Gastric and Esophageal Cancer Patients**

- **Sponsor**: Fox Chase Cancer Center
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 80%

**âœ“ Supporting Factors:**
- Patient has advanced gastric cancer, which is the primary condition studied in the trial.
- Patient's cancer is HER2-positive (IHC 3+), which qualifies under the inclusion criteria for HER2-overexpressing tumors.
- Patient has received prior HER2-directed therapy (trastuzumab) and completed it more than 2 weeks before C1D1.
- Patient's ECOG performance status is 2, which is acceptable as per trial criteria.

**? Uncertainties:**
- Normal organ and marrow function parameters are not provided; levels of leukocytes, absolute neutrophil count, platelets, hemoglobin, liver function tests (AST/ALT), and creatinine need to be confirmed.
- Left Ventricular Ejection Fraction status is not provided.
- Potential uncontrolled intercurrent illnesses are not specified.

**Assessment:**
> The patient matches the disease type specified in the trial, is a previously treated patient which is acceptable, and meets the biomarker criteria. The primary uncertainties revolve around normal organ function and specific health metrics that were not provided.

---

### [NCT04107077](https://clinicaltrials.gov/study/NCT04107077)

**A Phase IIa Study of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and PD-L1 Expression in Gastric Cancer With Peritoneal Metastases**

- **Sponsor**: University of Chicago
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 75%

**âœ“ Supporting Factors:**
- Age is 55 years, which is greater than 18 years
- ECOG performance status is 2
- Patient has histologically confirmed gastric cancer with peritoneal carcinomatosis
- Prior systemic chemotherapy completed for more than 2 to 4 months
- PD-L1 expression is CPS 45

**? Uncertainties:**
- Adequate organ function tests (leukocytes, absolute neutrophil count, platelets, total bilirubin, AST/ALT, creatinine/GFR) not provided
- No information on uncontrolled intercurrent illness and psychiatric illness/social situations

**Assessment:**
> The patient's profile indicates a match for the trial's disease type as he has gastric cancer with peritoneal metastases. He is also previously treated, which aligns with the trial's eligibility for patients who have completed prior systemic chemotherapy. The ECOG status and age meet criteria. However, there are uncertainties regarding organ function and potential uncontrolled illnesses.

---

## ðŸŸ¡ MEDIUM Likelihood (1 trials)

### [NCT06242470](https://clinicaltrials.gov/study/NCT06242470)

**A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors**

- **Sponsor**: MacroGenics
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 65%

**âœ“ Supporting Factors:**
- Age: 55
- Sex: male
- Cancer type: gastric cancer
- ECOG status: 2
- Biomarkers: HER2 positive, MSI-High
- PD-L1: CPS 45
- Country: United States

**? Uncertainties:**
- Prior therapies may not fit the required treatment line as the patient has been previously treated.
- Adequate performance and laboratory parameters are not explicitly confirmed in the profile.

**Assessment:**
> The patient's cancer type (gastric cancer) aligns with the trial's target indication. However, the patient has prior systemic therapies, raising uncertainty about the required treatment line for eligibility. Other specifics regarding performance status and laboratory parameters are not provided, contributing to a medium confidence level.

---

## ðŸŸ  LOW Likelihood (1 trials)

### [NCT03935893](https://clinicaltrials.gov/study/NCT03935893)

**A Phase 2 Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients With Advanced Solid Cancers**

- **Sponsor**: Udai Kammula
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 25%

**âœ“ Supporting Factors:**
- Disease type matches as gastric cancer is included in the trial

**âœ— Potential Conflicts:**
- ECOG status is 2, but trial requires ECOG 0 or 1
- Patient has prior systemic therapies, but they may have exhausted conventional systemic therapy options threshold.

**? Uncertainties:**
- Organ function labs, including hematology and chemistry values, are not provided.

**Assessment:**
> The patient's cancer type matches the trial requirements, but the ECOG status of 2 does not meet the eligibility criteria, and there are uncertainties regarding organ function laboratories. Additionally, the patient's extensive prior therapies may conflict with the requirement to have exhausted conventional systemic treatments.

---

## Excluded (90 trials)

### Excluded by Fast Filter

| NCT ID | Reason |
|--------|--------|
| [NCT02693535](https://clinicaltrials.gov/study/NCT02693535) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT03607890](https://clinicaltrials.gov/study/NCT03607890) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04114136](https://clinicaltrials.gov/study/NCT04114136) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04383262](https://clinicaltrials.gov/study/NCT04383262) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05176665](https://clinicaltrials.gov/study/NCT05176665) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05239546](https://clinicaltrials.gov/study/NCT05239546) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05267626](https://clinicaltrials.gov/study/NCT05267626) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05273307](https://clinicaltrials.gov/study/NCT05273307) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05417594](https://clinicaltrials.gov/study/NCT05417594) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05592626](https://clinicaltrials.gov/study/NCT05592626) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05709574](https://clinicaltrials.gov/study/NCT05709574) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05855200](https://clinicaltrials.gov/study/NCT05855200) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05919264](https://clinicaltrials.gov/study/NCT05919264) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05997056](https://clinicaltrials.gov/study/NCT05997056) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06006923](https://clinicaltrials.gov/study/NCT06006923) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06356311](https://clinicaltrials.gov/study/NCT06356311) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06590454](https://clinicaltrials.gov/study/NCT06590454) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06628310](https://clinicaltrials.gov/study/NCT06628310) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06710847](https://clinicaltrials.gov/study/NCT06710847) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06730750](https://clinicaltrials.gov/study/NCT06730750) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| ... | *and 22 more* |

### Excluded by Eligibility Assessment

| NCT ID | Sponsor | Reason |
|--------|---------|--------|
| [NCT05753306](https://clinicaltrials.gov/study/NCT05753306) | Mayo Clinic | Patient has malignant ascites at the time of study enrollment, which is an exclusion criteria. |
| [NCT04573231](https://clinicaltrials.gov/study/NCT04573231) | University of Wiscon | Patient has gastric cancer (not breast cancer), which does not match the trial's indication. |
| [NCT04899908](https://clinicaltrials.gov/study/NCT04899908) | Dana-Farber Cancer I | Patient does not have brain metastases, which is a requirement for the trial. |
| [NCT04787042](https://clinicaltrials.gov/study/NCT04787042) | Simcha IL-18, Inc. | ECOG status of 2 does not meet the trial requirement of ECOG 0 or 1. |
| [NCT05086692](https://clinicaltrials.gov/study/NCT05086692) | Medicenna Therapeuti | ECOG status is 2, trial requires ECOG 0-1 |
| [NCT05455619](https://clinicaltrials.gov/study/NCT05455619) | SynDevRx, Inc. | Patient has gastric cancer while trial studies HR+/HER2-negative breast cancer. |
| [NCT05696626](https://clinicaltrials.gov/study/NCT05696626) | Sermonix Pharmaceuti | Patient has gastric cancer while the trial is for metastatic breast cancer, hence the disease type does not match. |
| [NCT05546268](https://clinicaltrials.gov/study/NCT05546268) | Monte Rosa Therapeut | Patient has gastric cancer while the trial is for NSCLC, SCLC, high-grade neuroendocrine cancer, DLBCL, and tumors with L-MYC or N-MYC amplification. |
| [NCT05748834](https://clinicaltrials.gov/study/NCT05748834) | SCRI Development Inn | Patient has gastric cancer while the trial is focusing on HER2+ metastatic breast cancer. |
| [NCT05950945](https://clinicaltrials.gov/study/NCT05950945) | Daiichi Sankyo | Patient has gastric cancer, but the trial is for breast cancer. |
| [NCT06362369](https://clinicaltrials.gov/study/NCT06362369) | 7 Hills Pharma, LLC | ECOG performance status is 2, while the trial requires ECOG 0 or 1. |
| [NCT06695845](https://clinicaltrials.gov/study/NCT06695845) | Jazz Pharmaceuticals | Patient has ECOG status 2, trial requires ECOG status 0 or 1 |
| [NCT02012699](https://clinicaltrials.gov/study/NCT02012699) | University of Nebras | Patient has prior therapies (FOLFOX, trastuzumab, pembrolizumab) while the trial does not specify if it includes previously treated patients. |
| [NCT06241456](https://clinicaltrials.gov/study/NCT06241456) | Fate Therapeutics | ECOG status is 2, while trial requires ECOG status of 0 or 1 |
| [NCT05544929](https://clinicaltrials.gov/study/NCT05544929) | Novartis Pharmaceuti | Patient's cancer type (gastric cancer) does not match the conditions studied (primarily focused on non-small cell lung, melanoma, renal cell, and others, specifically including esophagogastric cancer but does not specify gastric cancer). |
| [NCT05608252](https://clinicaltrials.gov/study/NCT05608252) | Adrienne G. Waks | Patient has gastric cancer while trial is for metastatic HR+/HER2- breast cancer. This mismatch leads to exclusion. |
| [NCT03551951](https://clinicaltrials.gov/study/NCT03551951) | University of Missou | Trial requires patients to have resectable solid primary cancers; patient has metastatic gastric cancer. |
| [NCT04191551](https://clinicaltrials.gov/study/NCT04191551) | Stanford University | Patient has metastatic gastric cancer, but trial focuses on precancerous gastric conditions, which do not align with the patient's current disease status. |
| [NCT05038098](https://clinicaltrials.gov/study/NCT05038098) | M.D. Anderson Cancer | Patient has metastatic gastric adenocarcinoma but the trial requires patients with biopsy-proven gastric cancer undergoing curative-intent gastrectomy and no distant metastases. |
| [NCT04553770](https://clinicaltrials.gov/study/NCT04553770) | Jonsson Comprehensiv | Patient has gastric cancer (not eligible for breast cancer trial) |
| ... | ... | *and 28 more* |

## Search Terms Used

| Term | Source | Confidence |
|------|--------|------------|
| HER2 positive | manual | 1.0 |
| HER2positive | manual | 0.9 |
| HER2-positive | manual | 0.9 |
| MSI-High | manual | 1.0 |
| gastric cancer | manual | 1.0 |
| HER2 positive gastric cancer | manual | 1.0 |
| MSI-High gastric cancer | manual | 1.0 |
| HER2 positive metastatic gastric cancer | llm | 0.9 |
| stomach cancer | llm | 0.8 |
| gastric adenocarcinoma | llm | 0.8 |
| HER2+ | llm | 0.9 |

## Information That Would Improve Matches

The following patient data was not provided but would help refine eligibility assessment:

- **Organ function labs** (hematology, liver, renal) - required by all interventional trials
- **Measurable disease status** (per RECIST 1.1) - required for most therapeutic trials
- **Life expectancy estimate** - many trials require â‰¥3 months
